Cyclooxygenase-2 Expression and Colorectal Cancer
Cyclooxygenase-2 Expression and Colorectal Cancer
A pathogenic role for cyclooxygenase-2 has been suggested by the epidemiologic observational studies that demonstrate a reduced rate of colorectal adenomas and carcinomas in persons who have taken NSAIDs over long periods. Correspondingly, COX-2 has been found in human colorectal cancer, and interruption of COX-2 either by COX-2 specific inhibitors or COX-2 gene blockade substantially reduces polyp growth in mouse models of polyposis coli.
In order to further define the role of COX-2 in colorectal cancer, Sheehan and colleagues studied 76 patients with colorectal cancer, who had staining of the tumor epithelial cells with anti-COX-2 antibody. The degree of staining on a four-point scale (grade 1 = least staining, grade 4 = most staining) correlates with the degree of COX-2 expression. Survival, from the time of diagnosis to death, was compared in relation to COX-2 grade of staining.
All of the colorectal tumors stained positively for COX-2, dominantly in the cytoplasm of epithelial cells and/or vascular endothelial cells. In colon tissue samples from control samples without cancer, no COX-2 expression was demonstrable.
Numerous negative cancer outcome predictors were associated with COX-2 expression. For instance, there was a direct relationship between COX-2 staining and Dukes cancer stage, tumor size, and lymph node metastasis. Survival for 5 years was 40.5% in patients with grade 2-4 COX-2 staining, compared to 91.6% in patients with grade 1 COX-2 staining.
Sheehan et al acknowledge that it remains uncertain whether COX-2 plays a causal role in cancer and its progression, or is just an incidental association. Nonetheless, data with NSAIDs like sulindac have shown reductions in polyp number and size in high-risk populations, suggesting that COX activity may be not only pathogenic, but also modifiable.
Sheehan KM, et al. JAMA 1999;282: 1254-1257.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.